BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
Status:
Completed
Trial end date:
2021-01-08
Target enrollment:
Participant gender:
Summary
This multi-center, double-blind, placebo-controlled, randomized Phase 2 trial will study the
safety, tolerability, and efficacy of bardoxolone methyl in patients hospitalized with
confirmed COVID-19. The trial will include approximately 40 patients and is designed to
provide an early interim analysis of safety. Patients will be randomized using permuted block
randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20
mg) or matching placebo and treatment will be administered for the duration of
hospitalization (until recovery), with a maximum treatment duration of 29 days.